CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis. In this study, the improvements in disease-related parameters resulting from IMO-3100 treatment were associated with suppression of interleukin 6 (IL-6) and complement C3 and with induction of interleukin 10 (IL-10). The presentation (#T65), entitled “Treatment with IMO-3100, a novel TLR7 and TLR9 dual antagonist, inhibits disease development in a mouse model of collagen antibody-induced arthritis (CAIA),” is being made at the Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) held June 23-26, 2011 in Washington, D.C. IMO-3100 is an antagonist of Toll-like Receptor (TLR) 7 and TLR9 and is in clinical development for the treatment of autoimmune diseases.
